Date: 2014-08-19
Type of information: R&D agreement
Compound: new technologies for targeted epigenomic analysis
Company: Roche (Switzerland) the Garvan Institute of Medical Research (USA - CA)
Therapeutic area:
Type agreement:
Action mechanism:
Disease:
Details: * On August 19, 2014, Roche and the Garvan Institute of Medical Research announced a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing. Under the terms of the two-year discovery agreement, the Garvan Institute and Roche will collaborate to develop new methods to accurately analyze regions of the epigenome. The collaboration brings together the world-leading genomics expertise and infrastructure at the Garvan Institute and the best-in-class products for target enrichment from Roche NimbleGen, part of the Roche Sequencing Unit. As part of the agreement, the SeqCap Target Enrichment System from Roche will be used by scientists at the Garvan Institute to further their research in epigenetic influences on human diseases.
Financial terms: Financial terms of the collaboration are not disclosed.
Latest news:
